Filippo A. Canale

🎹 🎼 Hematologist MD - BMT Unit @GOM_rc
Reggio Calabria, Italy

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION

Marek Trněný shares primary results from the phase II CHEPA trial evaluating BV-CHEP in patients with newly diagnosed CD30+ PTCL eligible for auto-HSCT, with integrated exploratory ctDNA analysis (N = 33).

The primary endpoint was met, with 76% of patients achieving CMR at EoT; the ORR was 91% across the full cohort. At a median follow-up of 29.6 months, 2-year PFS and OS were 78% and 90%, respectively. Grade 3–4 AEs occurred in 81.8% of patients are were largely hematological: neutropenia (78.8%), thrombocytopenia (18.2%), febrile neutropenia (15.2%), and anemia (15.2%). No Grade 5 events were reported. Baseline ctDNA load correlated with TMTV (r = 0.68; p = 0.00086) and PIT (p = 0.04395). Compared with FFPE tumor tissue, plasma detected more TCR clones (87% vs 77%) and tumor-specific mutations (91% vs 81%); combined plasma and FFPE approaches enabled MRD monitoring in 100% of cases.

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#lymphoma #lymsm #MedicalCongress @MarekTrnenyDr @CharlesUniPRG

[Blood Journals Portfolio @BloodPortfolio]

Elevation of BCMA cell surface expression via proteasome inhibition augments and restores anti–BCMA CAR T-cell activity. Read in Blood: https://t.co/U2SobHqLq8

[Blood Journals Portfolio @BloodPortfolio]

New CT-CI score is associated with survival after CAR-T therapy. Comorbidities and fear of increased toxicity should not preclude patients from this effective therapy. Read in Blood Advances: https://t.co/Hyg3LI2rNo

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH25 #mmsm @ASH_hematology

Oral myeloma- long term CARTITUDE-4 in standard risk patients

@End_myeloma

✅ 80% progression-free & off treatment at 2.5 years
✅ 93% of 1-year responders remained progression-free at 2.5 years
✅ 100% of MRD-negative CR patients progression-free at 2.5 years
✅ No IEC-parkinsonism events, low non-relapse mortality

[Filippo A. Canale @filcan87]

#cart #ebmt #bmt #hematology #lymphoma #telemedicine #covid

[Gaurav Prakash M.D. @DrGPrakash]

How to read an HLA report?
A thread 🧵✍️on understating HLA typing for BMT

Key slides from my talk at #ISBMT Annual Meeting
(1/7) @IsbmtU @ASTCT @ASTCT_Journal @ISMPOofficial @ishbtHematology

[GvHD Hub @gvhd_hub]

CONGRESS #EBMT23 | Leo Luznik @HopkinsMedicine presents the keynote lecture on PTCy during the opening ceremony of EBMT23. He talks through the the history of the use of PTCy then addresses the current unknowns and future frontiers #bmtsm #GvHD

[Reyes Martín Rojas @Reyes_MartinMD]

Published today @BloodJournal ➡️ Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes https://t.co/pbQtHmoUnp #AML #MDS

[Filippo A. Canale @filcan87]

It's time for definitely stop fluoroquinolone #infection #prophylaxis. #EBMT2023 #EBMT23

[Filippo A. Canale @filcan87]

Ready for day 2 of #EBMT23 in #paris #EBMT2023

[Filippo A. Canale @filcan87]

#EBMT23

[Filippo A. Canale @filcan87]

@TheEBMT #EBMT2023 interesting session about lung #gvhd

[Hematologia ICO Hospitalet @HematICO_Hosp]

Dra Eva Gonzalez Barca ⁦@ICO_oncologia ⁦@HHospitalet⁩ et al: Extranodal natural killer/T‐cell #lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets https://t.co/hlZr8fpsNe

[British Journal of Haematology @BrJHaem]

Now Free to Read: How I manage mantle cell lymphoma: indolent versus aggressive disease https://t.co/2rztFYtxd4

@mattwilson2287 @tobyeyre82 @chanyooncheah #lymsm #lymphoma

[Filippo A. Canale @filcan87]

@HematoRules DSA?

[Tania Jain @TaniaJain11]

More thoughts on “How I Treat Cytopenias after CAR T-cell Therapy” - ScienceDirect ⁦@DrFredLocke⁩ and Dr Tim Olson ⁦@BloodJournal⁩ ⁦@NiraliShahMD⁩ ⁦@fabianaperna⁩ https://t.co/9klEXtvVO4

[Vittorio di Trapani @vditrapani]

Quante volte, prima di esprimere una opinione, avete riflettuto sul fatto che se siete nati dal lato "giusto" del mondo non è merito ma è solo fortuna?

[Felipe Peña-Muñoz @HematoRules]

⁦👏🏼👏🏼👏🏼 nice job 👏🏼👏🏼👏🏼

@AnnaSureda5⁩ ⁦@TheEBMT⁩ ⁦@albertomussetti ⁦@HHospitalet⁩ ⁦@ICO_oncologia ⁦@idibell_cat⁩

Haplo vs MUD #HSCT Using Post-Transplantation Cyclophosphamide for #Lymphomas https://t.co/ZNCpKO2XDq

[Yi Lin @YiLinMDPhD]

While severe CRS is now less common with #CART, HLH-like syndrome, now termed IEC-HS, remains challenging to manage. Honored to be part of the group for @ASTCT guideline. Special shout-out to @NiraliShahMD to lead the panel to navigate this complex topic! https://t.co/w5XI67LE5x

[SUxGIÙ @giuliogianca]

@giubileif